Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials
Maintenance support following prescription GLP-1 therapy
Sanjay Bharti, MD , our comprehensive GLP-1 program is designed to support your unique health needs
We are with you every step of the way
stands as the foremost national market for GLP1 receptor agonists, fueled by its sophisticated healthcare infrastructure, effective reimbursement mechanisms, and aggressive public awareness campaigns
Upon activation of adenosine monophosphate (AMP)-activated protein kinase (AMPK), berberine enhances insulin sensitivity, reduces hepatic glucose output, and has been shown in animal models to increase GLP-1 secretion, although this mechanism has not yet been confirmed in large human trials